Results 171 to 180 of about 58,665 (272)

Matsupexole: A novel nonergot dopamine receptor agonist with sustained efficacy in a rat model of Parkinson's disease and limited off‐target activity

British Journal of Pharmacology, EarlyView.
Background and Purpose Dopamine receptor agonists, particularly targeting the dopamine D2L receptor (D2LR), have been used to treat Parkinson's disease (PD). However, valvular heart disease and somnolence, mainly caused by activating the serotonin 5‐HT2B receptor (5‐HT2BR) and dopamine D3 receptor (D3R), respectively, currently challenge their clinical
Takayuki Suzuki, Fumiki Oana, Masaki Oota, Yuma Handa, Osamu Kaminuma   +4 more
wiley   +1 more source

Novel drugs approved by the EMA, the FDA and the MHRA in 2025: A year in review

British Journal of Pharmacology, EarlyView.
Abstract In the 2025 novel drug mini‐review, one can take a full measure of the ingenuity that underlies current drug design and development, despite the year's smaller harvest (46 novel drugs) compared to 2024 (53) and 2023 (70). 54% of the novel drugs are first‐in‐class (FIC).
Andreas Papapetropoulos, Stavros Topouzis, Steve P. H. Alexander, Miriam M. Cortese‐Krott, Zsuzsanna Helyes, Kirill Martemyanov, Claudio Mauro, Nithyanandan Nagercoil, Reynold A. Panettieri Jr, Hemal H. Patel, Rainer Schulz, Barbara Stefanska, Gary J. Stephens, Nathalie Vergnolle, Xin Wang, Stephen Ward, Péter Ferdinandy   +16 more
wiley   +1 more source

Impulse control disorders in patients with pituitary adenoma managed with or without dopamine agonists: a cross-sectional study from a UK centre. [PDF]

Pituitary
Hamblin R, White M, Fountas A, Karavitaki N.   +3 more
europepmc   +1 more source

Effects of Spiradoline Mesylate, a Selective κ-Opioid-Receptor Agonist, on the Central Dopamine System with Relation to Mouse Locomotor Activity and Analgesia

, 1993
Mineo Kunihara, Miwako Ohyama, Miyuki Nakano   +2 more
openalex   +1 more source

Effects of dopamine and selective dopamine agonists upon platelet accumulation in the cerebral and pulmonary vasculature of the rabbit [PDF]

, 1997
Michael Emerson, William Paul, Pierpaolo Ferlenga, C. Semeraro, Clive Page   +4 more
openalex   +1 more source

Novel Histopathologic Features of Diffuse Blue‐Gray Hyperpigmentation Associated With Kratom Use: A Case Report and Literature Review

Journal of Cutaneous Pathology, EarlyView.
ABSTRACT Background Drug‐induced hyperpigmentation accounts for 10%–20% of acquired pigmentary disorders and can be misdiagnosed for other causes such as melasma, post inflammatory changes, or heavy metal deposition. Kratom (Mitragyna speciosa), a Southeast Asian plant with an opioid‐like profile, has been increasingly used in the United States for ...
Rita Kamoua, Kristen Paradine, Craig A. Rohan, Mary McDaniel, Diane Perkins   +4 more
wiley   +1 more source

Comparative safety signals of dopamine agonists: psychiatric and cardiovascular risks derived from FDA adverse event reporting system (FAERS) data. [PDF]

BMC Pharmacol Toxicol
Mu L, Xu J, Ye X, Jiang Y, Yi Z.
europepmc   +1 more source

Cabergoline, Dopamine D2 Receptor Agonist, Prevents Neuronal Cell Death under Oxidative Stress via Reducing Excitotoxicity

, 2014
Haruki Odaka, Tadahiro Numakawa, Naoki Adachi, Yoshiko Ooshima, Shingo Nakajima, Yusuke Katanuma, Takafumi Inoue, Hiroshi Kunugi   +7 more
openalex   +2 more sources

Effective Treatment With Olanzapine for Burning Mouth Syndrome With Denture Intolerance in an Older Patient: A Case Report

Gerodontology, EarlyView.
ABSTRACT Introduction Burning mouth syndrome (BMS) is occasionally accompanied by denture intolerance. Case Presentation An 80‐year‐old woman with complaints of residual and relapsed intraoral pain and denture intolerance due to BMS was improved by olanzapine without severe adverse events, and her eating ability was successfully restored.
Motoko Watanabe, Masanao Inokoshi, Chizuko Maeda, Chihiro Takao, Risa Tominaga, Yasuyuki Kimura, Takahiko Nagamine, Akira Toyofuku   +7 more
wiley   +1 more source

Cortico-striatal circuit mechanisms drive the effects of D1 dopamine agonists on memory capacity in mice through cAMP/PKA signalling. [PDF]

Nat Commun
De Risi M, Cavezza D, Torromino G, Capalbo A, Cundin XB, Di Martino R, Alvino FG, Iemolo A, Speranza L, Perrone-Capano C, Crispino M, Cirillo C, Luini A, Sacco F, Grumati P, De Leonibus E.   +15 more
europepmc   +1 more source